Teriflunomide

Exposed non-exposed studies (cohort)

Study Country
Study period
Population source Exposure definition Non-exposure definition Sample size Rmk
Barataud-Reilhac A (Control exposed to IFN or GLA), 2019 France
2014 - 2016
All 15 to 49 year-old French women, identified as having Multiple Sclerosis (MS), not sterile, and benefiting from health insurance Pregnant MS women exposed to teriflunomide, i.e woman had taken it during pregnancy or did not follow the appropriate recommendations (accelerated disposal procedure) after treatment stop. exposed to other treatment, sick
Pregnant MS women exposed to interferons or glatiramer acetate (IFN-GA) during pregnancy.
47 / 673
Barataud-Reilhac A (Control unexposed, sick), 2019 France
2014 - 2016
All 15 to 49 year-old French women, identified as having Multiple Sclerosis (MS), not sterile, and benefiting from health insurance. Pregnant women exposed to teriflunomide, i.e woman had taken it during pregnancy or did not follow the appropriate recommendations (accelerated disposal procedure) after treatment stop. unexposed, sick
Pregnant women with no treatment (NOTT).
47 / 1538

Case-control studies (cohort)

Study Country
Study period
Case Control Sample size Rmk

See the method used to produce these results